Brief: Polyrizon Structures Clinical Strategy For Its Allergy Blocker Ahead Of FDA Pre-Submission Meeting
27/03/2025 12:26
March 27 (Reuters) - Polyrizon Ltd PLRZ.O: POLYRIZON STRUCTURES CLINICAL STRATEGY FOR ITS ALLERGY BLOCKER AHEAD OF FDA PRE-SUBMISSION MEETING POLYRIZON LTD - EXPECTS TO INITIATE CLINICAL TRIALS IN U.S. AND EUROPE IN LATE 2025 Source text: ID:nGNXb6nl5X Further company coverage: PLRZ.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Polyrizon
See all newsBrief: Polyrizon Files For U.S. Patent Application To Expand Ip Moat Around Intranasal Drug-Delivery Platform
Brief: Polyrizon Advances Towards Human Clinical Trials Secures First U.S. Clinical Site For Nasarix™ Allergy Blocker Clinical Trial
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:58 AM
Enters Agreements For Registered Direct Offering Of Ordinary Shares And Pre-Funded Warrants
U.S. STOCKS ON THE MOVE-Enovis, Cheniere, Packaging Corp of America